CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Alirocumab

Last Updated: December 7, 2015
Result type: Reports
Project Number: SR0469-000
Product Line: Common Drug Review

Generic Name: Alirocumab

Brand Name: Praluent

Manufacturer: Sanofi-aventis Canada Inc.

Indications: Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia

Submission Type: New

Project Status: Complete

Date Recommendation Issued: July 20, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions